Senseonics Holdings (SENS) Stock Forecast & Price Target

Senseonics Holdings is benefiting from a sharp inflection in commercial execution, with 3Q revenue reaching $19.6 million, up about 140% year over year, and U.S. revenue of $16.8 million rising roughly 160% on record new patient starts and shipment volume. The outlook is further supported by improving gross margin of about 62%, raised 2026 revenue guidance of $68 million to $70 million, and a growing recurring base as management expects roughly $40 million to $50 million of 2027 revenue from reorders. Its differentiated Eversense 365 platform, expanding direct-to-consumer demand, rising active prescriber participation, and incremental pump integrations strengthen the case for sustained share gains, while cash and equivalents of $126.6 million provide runway into 2028.

Senseonics Holdings is viewed negatively because it has incurred significant operating losses since inception and still faces substantial doubt about its ability to achieve sustained profitability or continue as a going concern without additional capital or materially better performance. Its results remain volatile, and the reliance on Ascensia for a substantial majority of future revenue creates concentration risk that could quickly pressure commercialization, while 3Q26 international sales of $2.8MM missed estimates and management cut expected O-U.S. sales to 15% of revenue, signaling weaker-than-expected traction abroad. Cash burn is also a major concern, with full-year usage expected at the high end of the prior range at $120MM, even as the company faces intense competition from Abbott, DexCom, and MiniMed, plus regulatory, reimbursement, and execution risks around future products.